Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine.

As key regulators of the cell proliferation cycle, cyclin-dependent kinases (CDKs) are attractive targets for the development of anti-tumor drugs. In the present study, harmine was identified from a collection of herbal compounds to be a specific inhibitor of Cdk1/cyclin B, Cdk2/cyclin A, and Cdk5/p25 with IC50 values at low micromoles. It displayed little effect on other serine/threonine and tyrosine kinases tested. The CDK inhibition by harmine is competitive with ATP-Mg2+, suggesting that it binds to the ATP-Mg2+-binding pocket of CDKs. In cytotoxicity assays, harmine exhibited a strong inhibitory effect on the growth and proliferation of carcinoma cells whereas it had no significant effect on quiescent fibroblasts. Further, harmine was found to block DNA replication in the carcinoma cells. Taken together, harmine is a selective inhibitor of CDKs and cell proliferation.

[1]  J. H. Wang,et al.  Purification and characterization of a pp60c-src-related tyrosine kinase that effectively phosphorylates a synthetic peptide derived from p34cdc2. , 1991, The Journal of biological chemistry.

[2]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[3]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[4]  Jerry H. Wang,et al.  Reconstitution of Neuronal Cdc2-like Kinase from Bacteria-expressed Cdk5 and an Active Fragment of the Brain-specific Activator , 1995, The Journal of Biological Chemistry.

[5]  T. Ohira,et al.  Effects of β- and γ-carboline derivatives on DNA topoisomerase activities , 1996 .

[6]  L. Meijer,et al.  Chemical inhibitors of cyclin-dependent kinases. , 1996, Trends in cell biology.

[7]  Kazuyuki Takata,et al.  Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo , 2003, Neuron.

[8]  L. Tsai,et al.  Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration , 1999, Nature.

[9]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[10]  L. Meijer,et al.  Chemical inhibitors of cyclin-dependent kinases , 1997 .

[11]  R. Qi,et al.  Cyclin-dependent kinases in neural development and degeneration. , 2003, Journal of Alzheimer's disease : JAD.

[12]  G L Trainor,et al.  Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. , 2000, Journal of medicinal chemistry.

[13]  I. Matsuura,et al.  Demonstration of Cyclin-dependent Kinase Inhibitory Serine/Threonine Kinase in Bovine Thymus (*) , 1996, The Journal of Biological Chemistry.

[14]  L. Tsai,et al.  p35 and p39 Are Essential for Cyclin-Dependent Kinase 5 Function during Neurodevelopment , 2001, The Journal of Neuroscience.

[15]  C. Meester.  Genotoxic potential of beta-carbolines: a review. , 1995 .

[16]  J. H. Wang,et al.  A synthetic peptide derived from p34cdc2 is a specific and efficient substrate of src-family tyrosine kinases. , 1992, The Journal of biological chemistry.

[17]  P. Stawowy,et al.  The high-affinity binding of [3H]norharman ([3H]beta-carboline) to the ethanol-inducible cytochrome P450 2E1 in rat liver. , 1999, Biochemical pharmacology.

[18]  P. Nurse,et al.  Animal cell cycles and their control. , 1992, Annual review of biochemistry.

[19]  S. Elledge,et al.  Cdk inhibitors: on the threshold of checkpoints and development. , 1994, Current opinion in cell biology.

[20]  J. Lizcano,et al.  Inhibition of Monoamine Oxidase from Bovine Retina by β‐Carbolines , 1994 .

[21]  Veeranna,et al.  Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Li-Huei Tsai,et al.  A decade of CDK5 , 2001, Nature Reviews Molecular Cell Biology.

[23]  Li-Huei Tsai,et al.  Aberrant Cdk5 Activation by p25 Triggers Pathological Events Leading to Neurodegeneration and Neurofibrillary Tangles , 2003, Neuron.

[24]  K. Lee,et al.  Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs. , 1999, Bioorganic & medicinal chemistry letters.

[25]  R. Ramsay,et al.  Inhibition of Monoamine Oxidase A by β-Carboline Derivatives , 1997 .